Technical Analysis for TPTX - Turning Point Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 41.96 -0.99% -0.42
TPTX closed down 0.99 percent on Monday, July 15, 2019, on 1.26 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Up Down
See historical TPTX trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
20 DMA Support Bullish -0.99%
New 52 Week Closing High Bullish -4.07%
Pocket Pivot Bullish Swing Setup -4.07%
Narrow Range Bar Range Contraction -4.07%
NR7 Range Contraction -4.07%
Inside Day Range Contraction -4.07%
Up 3 Days in a Row Strength -4.07%
Shooting Star Candlestick Bearish -3.81%

Older signals for TPTX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients, and is planned to enter a registrational Phase 2 study in the second half of 2019. Turning Point’s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
Medicine Cancer Chemical Compounds Treatment Of Cancer Oncology Solid Tumors Non Small Cell Lung Cancer Antineoplastic Drugs Cancer Treatment Targeted Therapy Cancer Therapies Pyrrolidines Signal Transduction Protein Kinase Inhibitors Kinase
Is TPTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 47.7215
52 Week Low 24.21
Average Volume 204,250
200-Day Moving Average 0.0
50-Day Moving Average 38.2852
20-Day Moving Average 42.2085
10-Day Moving Average 42.954
Average True Range 2.5041
ADX 21.58
+DI 24.8194
-DI 19.9351
Chandelier Exit (Long, 3 ATRs ) 40.2092
Chandelier Exit (Short, 3 ATRs ) 44.1723
Upper Bollinger Band 44.9253
Lower Bollinger Band 39.4917
Percent B (%b) 0.45
BandWidth 12.873236
MACD Line 1.3866
MACD Signal Line 1.6153
MACD Histogram -0.2287
Fundamentals Value
Market Cap 677.82 Million
Num Shares 16.2 Million
EPS -1.33
Price-to-Earnings (P/E) Ratio -31.57
Price-to-Sales 0.85
Price-to-Book 1.17
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 45.11
Resistance 3 (R3) 45.23 44.29 44.59
Resistance 2 (R2) 44.29 43.49 44.24 44.41
Resistance 1 (R1) 43.13 43.00 42.66 43.01 44.23
Pivot Point 42.19 42.19 41.96 42.14 42.19
Support 1 (S1) 41.03 41.39 40.56 40.91 39.69
Support 2 (S2) 40.09 40.90 40.04 39.51
Support 3 (S3) 38.93 40.09 39.34
Support 4 (S4) 38.81